Table 1 Summary of patient demographics
Patients | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
Age (y) | 72 | 76 | 87 | 54 | 89 | 76 | 60 | 80 | 47 | 64 |
Sex | M | M | F | M | M | F | F | F | M | M |
Weight (kg) | 101 | 115 | 69 | 109 | 70 | 66 | 82 | 83 | 74 | 60 |
LOS | 35 | 31 | 36 | 81 | 55 | 10 | 18 | 11 | 35 | 20 |
RFA | Covid-19 | Fournier gangrene | Pneumonia | Bowel perforation | UTI | Ischemic colitis | Bleeding pelvic tumor | VHD | Covid-19 | Symptomatic thrombocytopenia |
Comorbidities | ||||||||||
AAA | ✘ | |||||||||
Autoimmune disease | ✘ | |||||||||
CAD | ✘ | ✘ | ✘ | ✘ | ✘ | |||||
COPD | ✘ | |||||||||
DM | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ||||
G6PD deficiency | ✘ | |||||||||
HTN | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ||||
Malignancy | ✘ | ✘ | ✘ | ✘ | ||||||
VHD | ✘ | ✘ | ||||||||
Renal function | HDD-ESRD | HDD-ESRD | CKD stage 4 | HDD-ESRD | CKD stage 4 | CKD stage 4 | HDD-ESRD | CKD stage 4 | AKI (CrCl 30 mL/min) | HDD-ESRD |
Recent Surgery | Vascular | Cardiac | Oncologic | Cardiac | ||||||
Indication for anticoagulation | AF | AF | AF | VTE | AF | VTE | Acute limb ischemia | AF | VTE | VTE |
4T score | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 5 | 4 | 5 |
First dose (mg) | 5 | 7.5 | 5 | 7.5 | 5 | 2.5 | 7.5 | 2.5 | 7.5 | 5 |
First anti-Xa | 0.60 | 0.38 | 0.42 | 0.60 | 0.60 | 0.39 | 0.22 | 0.22 | 1.07 | 0.79 |
# of doses needed to reach therapeutic level | 1 | 2 | 2 | 1 | 1 | 2 | - | 2 | 1 | 1 |
Total days on Fondaparinux | 5 | 10 | 20 | 7 | 15 | 14 | 2 | 4 | 11 | 10 |
Number of anti-Factor Xa measures | 4 | 5 | 14 | 6 | 10 | 11 | 2 | 5 | 7 | 5 |
Signs of bleed | ✘ chest tubes /pneumothorax | |||||||||
Drop in platelets after the start of fondaparinux | increase | increase | increase | ✘ moderate drop platelets 50–100 × 10 9 /L | ✘ moderate drop platelets 50–100 × 10 9 /L | increase | stable | stable | ✘ severe drop (malignancy) platelets less than 50 × 10 9 /L | ✘ severe drop (malignancy) platelets less than 50 × 10 9 /L |
New thrombosis | ✘ | |||||||||